Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C14H17N5 |
Molar mass | 255.325 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice. [1]
It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it. [2]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C14H17N5 |
Molar mass | 255.325 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice. [1]
It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it. [2]